CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $5.41M, lower than 95% of all stocks globally
- PositionPrice-to-book is 34.37×, higher than 95% of its Biotechnology peers (median 2.97×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.16TKRW2.28B · vs all stocks (USD)
Revenue (TTM)
7.51BKRW5.41M · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.48xvs all stocks
52-Week Change
61.11%vs all stocks
Market Capitalization
3.16TKRW2.28B · vs all stocks (USD)
Enterprise Value
3.21TKRW2.31B · vs all stocks (USD)
Forward P/E
-74.71xvs Biotechnology peers
Price to Book (MRQ)
34.37xvs Biotechnology peers
Enterprise to Revenue
426.68xvs Biotechnology peers
Enterprise to EBITDA
-53.45xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-824.00%vs Biotechnology peers
Return on Assets (TTM)
-35.08%vs Biotechnology peers
Return on Equity (TTM)
-69.86%vs Biotechnology peers
Revenue (TTM)
7.51BKRW5.41M · vs all stocks (USD)
Revenue per Share (TTM)
415.73KRWUpdated Aug 20, 2026Gross Profit (TTM)
7.51BKRW5.41M · vs all stocks (USD)
EBITDA (TTM)
-59.97BKRW-43.21M · vs all stocks (USD)
Net Income (TTM)
-50.60BKRW-36.46M · vs all stocks (USD)
Operating Cash Flow (TTM)
-75.49BKRW-54.40M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-41.20BKRW-29.68M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
7.51BKRWFY2025 · Dec 31, 2025Gross Profit
7.51BKRWFY2025 · Dec 31, 2025Operating Income
-54.38BKRW-39.19M · vs all stocks (USD)
Pre-tax Income
-50.63BKRWFY2025 · Dec 31, 2025Income Tax Expense
-7.93BKRWFY2025 · Dec 31, 2025Net Income
-42.71BKRWFY2025 · Dec 31, 2025EBIT
-47.99BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-50.81BKRWFY2025 · Dec 31, 2025Research & Development
31.01BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
4.51BKRWFY2025 · Dec 31, 2025Other Operating Expenses
487.73MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
1.96BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
2.65BKRWFY2025 · Dec 31, 2025EPS (Basic)
-2.37KKRWFY2025 · Dec 31, 2025EPS (Diluted)
-2.37KKRWFY2025 · Dec 31, 2025Basic Shares Outstanding
17.99MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
17.99MSharesFY2025 · Dec 31, 2025Operating Cash Flow
-71.11BKRWFY2025 · Dec 31, 2025Free Cash Flow
-72.73BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
35.74BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-50.63BKRWFY2025 · Dec 31, 2025Stock-based Compensation
8.37BKRWFY2025 · Dec 31, 2025Other Non-cash Items
685.68MKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-22.06MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-29.51BKRWFY2025 · Dec 31, 2025Capital Expenditures
-1.62BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-32.81MKRWFY2025 · Dec 31, 2025Purchase of Investments
-120.41BKRWFY2025 · Dec 31, 2025Sale of Investments
89.61BKRWFY2025 · Dec 31, 2025Other Investing Activity
-10.00KRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-32.42BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
85.99BKRWFY2025 · Dec 31, 2025Other Financing Charges
-1.36BKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
130.99BKRWFY2025 · Dec 31, 2025Shares Outstanding
18.33MSharesUpdated Aug 20, 2026Float Shares
10.68MSharesUpdated Aug 20, 2026% Held by Insiders
39.47%vs all stocks
% Held by Institutions
8.36%vs all stocks
Total Cash (MRQ)
118.82BKRW85.62M · vs all stocks (USD)
Total Cash per Share (MRQ)
6.49KKRWUpdated Aug 20, 2026Total Debt (MRQ)
35.62BKRW25.67M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3878xvs Biotechnology peers
Current Ratio (MRQ)
11.19xvs Biotechnology peers
Book Value per Share (MRQ)
5.02KKRWUpdated Aug 20, 2026Total Assets
171.23BKRW123.38M · vs all stocks (USD)
Total Current Assets
148.31BKRWFY2025 · Dec 31, 2025Total Liabilities
67.44BKRWFY2025 · Dec 31, 2025Total Non-current Assets
22.93BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
59.54BKRWFY2025 · Dec 31, 2025Total Current Liabilities
7.90BKRWFY2025 · Dec 31, 2025Cash
4.00BKRWFY2025 · Dec 31, 2025Cash Equivalents
31.74BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
35.74BKRWFY2025 · Dec 31, 2025Other Short-term Investments
99.94BKRWFY2025 · Dec 31, 2025Accounts Receivable
21.52MKRWFY2025 · Dec 31, 2025Short-term Debt
992.79MKRWFY2025 · Dec 31, 2025Other Current Liabilities
960.00KRWFY2025 · Dec 31, 2025Long-term Debt
38.82BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
-650.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
9.20BKRWFY2025 · Dec 31, 2025Retained Earnings
-232.22BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
103.80BKRW74.79M · vs all stocks (USD)
Treasury Stock
50.03MKRWFY2025 · Dec 31, 202552-Week Low
97.50KKRWUpdated Aug 20, 202652-Week High
375.50KKRWUpdated Aug 20, 202652-Week Change
61.11%vs all stocks
Beta
1.48xvs all stocks
50-Day MA
165.90KKRWUpdated Aug 20, 2026200-Day MA
230.91KKRWUpdated Aug 20, 2026Avg 10-Day Volume
128.91KSharesUpdated Aug 20, 2026Avg 30-Day Volume
103.98KSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-2.37KKRWUpdated Aug 20, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 34.37×, higher than 95% of its Biotechnology peers (median 2.97×)Significant
Price-to-book: 34.37Industry median: 2.97Industry P95: 23.50Peers compared: 261
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 131.911
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $5.41M, lower than 95% of all stocks globallySignificant
Revenue (USD): 5,413,067.338Global P5: 30,274,777.221
Market cap is $2.28B, above the global median of $1.15BNotable
Market cap (USD): 2,278,620,683.978Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangzhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nanobiotix S.A.
Tier 1ProductionApproval-Gated PipelineRule
Pavella Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Agios Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pfizer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nektar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Granules India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Neogen Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Wave Life Sciences Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Sealsq Corp
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Enovix Corporation
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC